Your browser doesn't support javascript.
loading
[French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment]. / Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures ­ Principes généraux de traitement.
Barry, Béatrix; Dolivet, Gilles; Clatot, Florian; Huguet, Florence; Abdeddaim, Cyril; Baujat, Bertrand; Blanchard, Nicolas; Calais, Gilles; Carrat, Xavier; Chatellier, Anne; Coste, Florence; Cupissol, Didier; Cuvelier, Philippe; De Mones Del Pujol, Erwan; Deneuve, Sophie; Duffas, Olivier; Dupret-Bories, Agnès; Even, Caroline; Evrard, Camille; Evrard, Diane; Faivre, Sandrine; Fakhry, Nicolas; Garrel, Renaud; Gorphe, Philippe; Houliat, Thierry; Kaminsky, Marie-Christine; Krebs, Lorraine; Lapeyre, Michel; Lindas, Pierre; Malard, Olivier; Mirghani, Haitham; Mondina, Michel; Moriniere, Sylvain; Mouawad, François; Pestre-Munier, Julia; Pham Dang, Nathalie; Picard, Annabelle; Ramin, Lionel; Renard, Sophie; Salvan, Didier; Schernberg, Antoine; Sire, Christian; Thariat, Juliette; Vanbockstael, Julie; Vo Tan, Dan; Wojcik, Thomas; Klein, Isabelle; Block, Véronique; Baumann-Bouscaud, Lorraine; De Raucourt, Dominique.
Afiliación
  • Barry B; AP-HP, hôpital Bichat-Claude-Bernard, ORL et CCF, Paris (75), France.
  • Dolivet G; Institut de cancérologie de Lorraine, ORL et CCF, Nancy (54), France. Electronic address: g.dolivet@nancy.unicancer.fr.
  • Clatot F; Centre Henri-Becquerel, Rouen (76), France.
  • Huguet F; AP-HP, hôpital Tenon, Paris (75), France.
  • Abdeddaim C; Centre Oscar-Lambret, Lille, France.
  • Baujat B; AP-HP, hôpital Tenon, ORL et CCF, Paris, France.
  • Blanchard N; Groupe médical Les Dentellières, Valenciennes, France.
  • Calais G; CHU de Tours, Tours, France.
  • Carrat X; Bordeaux, France.
  • Chatellier A; CHU de Caen, CMF, Caen, France.
  • Coste F; CHU de Poitiers, Poitiers, France.
  • Cupissol D; Institut du cancer, Montpellier, France.
  • Cuvelier P; Centre hospitalier Oloron, ORL et CCF, Oloron-Sainte-Marie, France.
  • De Mones Del Pujol E; CHU de Bordeaux, ORL et CCF, Bordeaux, France.
  • Deneuve S; CHU de Rouen, ORL et CCF, Rouen, France.
  • Duffas O; Centre hospitalier de Libourne, ORL et CMF, Libourne, France.
  • Dupret-Bories A; Oncopole de Toulouse, ORL et CCF, Toulouse, France.
  • Even C; Institut Gustave-Roussy, Villejuif, France.
  • Evrard C; CHU de Poitiers, Poitiers, France.
  • Evrard D; AP-HP, hôpital Bichat-Claude-Bernard, ORL et CCF, Paris (75), France.
  • Faivre S; Hôpital Saint-Louis, Paris (75), France.
  • Fakhry N; Assistance publique-Hôpitaux de Marseille, ORL et CCF, Marseille, France.
  • Garrel R; CHU de Montpellier, ORL et CCF, Montpellier, France.
  • Gorphe P; Institut Gustave-Roussy, ORL et CCF, Villejuif, France.
  • Houliat T; Clinique Saint-Augustin, Bordeaux, France.
  • Kaminsky MC; Institut de cancérologie de Lorraine, Nancy, France.
  • Krebs L; Centre Icône, Reims-Bezannes, France.
  • Lapeyre M; Centre Jean-Perrin, Clermont-Ferrand, France.
  • Lindas P; Groupe UNEOS, ORL et CCF, Metz, France.
  • Malard O; CHU de Nantes, ORL et CCF, Nantes, France.
  • Mirghani H; AP-HP, HEGP, ORL et CCF, Paris, France.
  • Mondina M; ORL, Pau, France.
  • Moriniere S; CHU de Tours, ORL et CCF, Tours, France.
  • Mouawad F; CHU de Lille, ORL et CCF, Lille, France.
  • Pestre-Munier J; CHU de Limoges, Limoges, France.
  • Pham Dang N; CHU de Clermont-Ferrand, CMF, Clermont-Ferrand, France.
  • Picard A; Centre hospitalier de Périgueux, ORL et CCF, Périgueux, France.
  • Ramin L; CHU de Limoges, ORL et CCF, Limoges, France.
  • Renard S; Institut de cancérologie de Lorraine, Nancy, France.
  • Salvan D; Centre hospitalier Sud Francilien, ORL et CCF, Corbeil-Essonnes, France.
  • Schernberg A; Centre de cancérologie de la Porte de Saint-Cloud, Paris, France.
  • Sire C; Lorient, France.
  • Thariat J; Centre François-Baclesse, Caen, France.
  • Vanbockstael J; Institut de cancérologie de l'Ouest, Angers, France.
  • Vo Tan D; CHU d'Orléans, ORL, Orléans, France.
  • Wojcik T; Centre Oscar-Lambert, CMF, Lille, France.
  • Klein I; Dispositif Spécifique Régional du Cancer Grand Est - NEON, Nancy (54), France.
  • Block V; Dispositif Spécifique Régional du Cancer Grand Est - NEON, Nancy (54), France.
  • Baumann-Bouscaud L; Dispositif Spécifique Régional du Cancer Grand Est - NEON, Nancy (54), France.
  • De Raucourt D; Centre François-Baclesse, ORL et CCF, Caen (14), France.
Bull Cancer ; 111(4): 393-415, 2024 Apr.
Article en Fr | MEDLINE | ID: mdl-38418334
ABSTRACT

OBJECTIVES:

The management of upper aerodigestive tract cancers is a complex specialty. It is essential to provide an update to establish optimal care. At the initiative of the INCa and under the auspices of the SFORL, the scientific committee, led by Professor Béatrix Barry, Dr. Gilles Dolivet, and Dr. Dominique De Raucourt, decided to develop a reference framework aimed at defining, in a scientific and consensus-based manner, the general principles of treatment for upper aerodigestive tract cancers applicable to all sub-locations.

METHODOLOGY:

To develop this framework, a multidisciplinary team of practitioners was formed. A systematic analysis of the literature was conducted to produce recommendations classified by grades, in accordance with the standards of the French National Authority for Health (HAS).

RESULTS:

The grading of recommendations according to HAS standards has allowed the establishment of a reference for patient care based on several criteria. In this framework, patients benefit from differentiated care based on prognostic factors they present (age, comorbidities, TNM status, HPV status, etc.), conditions of implementation, and quality criteria for indicated surgery (operability, resectability, margin quality, mutilation, salvage surgery), as well as quality criteria for radiotherapy (target volume, implementation time, etc.). The role of medical and postoperative treatments was also evaluated based on specific criteria. Finally, supportive care must be organized from the beginning and throughout the patients' care journey.

CONCLUSION:

All collected data have led to the development of a comprehensive framework aimed at harmonizing practices nationally, facilitating decision-making in multidisciplinary consultation meetings, promoting equality in practices, and providing a state-of-the-art and reference practices for assessing the quality of care. This new framework is intended to be updated every 5 years to best reflect the latest advances in the field.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas Límite: Humans Idioma: Fr Revista: Bull Cancer Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas Límite: Humans Idioma: Fr Revista: Bull Cancer Año: 2024 Tipo del documento: Article País de afiliación: Francia